Proactive Investors - Run By Investors For Investors

Rhinomed Limited in halt on European sales of snoring product

Rhinomed Limited in halt on European sales of snoring product

Rhinomed Limited (ASX:RNO) has been granted an ASX trading halt in relation to European sales of its Mute over-the-counter snoring product.

The halt will last until the earlier of the announcement being made or the start of trade on Monday, 18th May 2015.

In April, the company expand its Australian wholesale pharmacy distribution footprint with Sigma Pharmaceuticals Limited (ASX:SIP) to include Mute.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full RNO profile View Profile

Rhinomed Ltd Timeline

Newswire
September 15 2015

Related Articles

1557403923_iron.jpg
May 09 2019
Here we take a look under the hood of Shield Therapeutics
test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile
lab worker
Mon
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use